BI 1493-0002 - Clinical Trial

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
A double-blind, randomised, placebo-controlled, parallel group, Phase IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI 765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis (IPF) BI 1493-0002
Principal Investigator
Lake D. Morrison, MD
Pulmonologist
Protocol Number
IRB: PRO00119034
NCT: NCT07036523
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Support Duke Health research or honor a loved one with a tribute gift.
Giving to Duke Health